Angle PLC - liquid biopsy company - Notes Medical University of Innsbruck, Austria publishes results from a study in metastatic prostate cancer patients. A key aim of the study was to demonstrate the ability to analyse gene expression in circulating tumour cells, which may help guide treatment decision-making for a diverse range of metastatic prostate cancer patients with differing tumour burdens and various prior therapies. Angle says longitudinal monitoring of one patient was undertaken using Angle's cell separation technology Parsortix, with five blood draws over a six-month period, and it was notable that the presence of circulating tumour cells declined.
"This study therefore provides further evidence of the capability of the Parsortix system to provide cancer cells for analysis from a simple blood test when tissue biopsy is not feasible, with the potential to guide future treatment decisions," says Angle Founder & Chief Executive Andrew Newland.
Current stock price: 117.00 pence
Year-to-date change: more than doubled from 47.75p on December 31
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Angle (AGL)